GPI-15715 Guilford

Matthew D Krasowski

Back

Journal article

GPI-15715 Guilford

Matthew D Krasowski

Current opinion in investigational drugs (London, England : 2000), Vol.6(1), pp.90-98

01/2005

PMID: 15675608

View Online

Abstract

GPI-15715 (PQ-1002, Aquavan), a water-soluble prodrug of propofol, is being developed by Guilford, under license from ProQuest, as a potential anesthetic agent. In May 2004, Guilford initiated phase III trials in the US to evaluate the sedative effects of this prodrug in several patient populations.

Anesthetics, Intravenous - adverse effects

Propofol - analogs & derivatives

Anesthetics, Intravenous - therapeutic use

Humans

Propofol - pharmacology

Clinical Trials as Topic

Prodrugs - adverse effects

Anesthetics, Intravenous - pharmacology

Animals

Prodrugs - therapeutic use

Prodrugs - pharmacology

Propofol - therapeutic use

Propofol - adverse effects

Details

Title: Subtitle: GPI-15715 Guilford
Creators: Matthew D Krasowski - Committee on Clinical Pharmacology & Pharmacogenomics and Department of Pathology, University of Chicago, Chicago, IL 60637, USA. kra3@harper.uchicago.edu
Resource Type: Journal article
Publication Details: Current opinion in investigational drugs (London, England : 2000), Vol.6(1), pp.90-98
Publisher: England
PMID: 15675608
ISSN: 1472-4472
Language: English
Date published: 01/2005
Academic Unit: Pathology
Record Identifier: 9984047696102771

Metrics

10 Record Views